[
    [
        {
            "time": "2023-10-17",
            "original_text": "Gilead-Galapagos Ink $5.1B Deal for Additional Compounds",
            "features": {
                "keywords": [
                    "Gilead",
                    "Galapagos",
                    "Deal",
                    "$5.1B",
                    "Additional Compounds"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Gilead-Galapagos Ink $5.1B Deal for Additional Compounds",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]